<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CLOFARABINE</span><br/>(clo-fa-ra'been)<br/><span class="topboxtradename">Clolar<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">purine antimetabolite</span><br/><b>Prototype: </b>6-Mercaptopurine<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL injection. Available in 20 mL vials.</p>
<h1><a name="action">Actions</a></h1>
<p>Clofarabine inhibits DNA repair within cancer cells, thus interfering with mitosis; it also disrupts the mitochondrial membrane,
         leading to cancer cell death. 
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Cytotoxic to rapidly proliferating and quiescent cancer cells.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of persons 121 y of age with relapsed or refractory acute lymphocytic leukemia (ALL) after at least 2 prior
         regimens.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category D); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic function impairment; thrombocytopenia; neutropenia; history of cardiac disease or hypotension.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Lymphocytic Leukemia</span><br/><span class="rdage">Adolescent/Child:</span> <span class="rdroute">IV</span> 52 mg/m<sup>2</sup>/d over 2 h for 5 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Do not give drugs with known renal toxicity during the 5 d of clofarabine administration.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Withdraw required dose from vial using a 0.2 micron filter syringe. Further dilute with D5W or NS prior to infusion.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span>  Give over 2 h. Note: It is recommended that IV fluids be given continuously throughout the 5 d of clofarabine administration.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store diluted solution at room temperature. Use within 24 h of mixing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Anxiety, depression, dizziness, headache, irritability, somnolence. <span class="typehead">CV:</span>
<span class="speceff-common">Tachycardia,</span> pericardial infusion, left ventricular systolic dysfunction (LSVT). <span class="typehead">GI:</span>
<span class="speceff-common">Vomiting, nausea, and diarrhea,</span> abdominal pain, constipation. <span class="typehead">Hematologic/Lymphatic:</span>
<span class="speceff-common">Anemia, leukopenia, thrombocytopenia, neutropenia, febrile neutropenia</span>. <span class="typehead">Hepatic:</span> Jaundice, hepatomegaly. <span class="typehead">Metabolic:</span> Anorexia, decreased appetite, edema, decreased weight. <span class="typehead">Musculoskeletal:</span> Arthralgia, back pain, myalgia. <span class="typehead">Respiratory:</span> Cough, dyspnea, epistaxis, pleural effusion, respiratory distress. <span class="typehead">Skin:</span> Dermatitis, contusion, dry skin, erythema, palmar-plantar erythrodysesthesia syndrome, pruritus. <span class="typehead">Body as a Whole:</span> Increase risk of infection. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 47% protein bound. <span class="typehead">Metabolism:</span> Negligible. <span class="typehead">Elimination:</span> Primarily eliminated unchanged in the urine. <span class="typehead">Half-Life:</span> 5.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs frequently during infusion of clofarabine.</li>
<li>Monitor closely for S&amp;S of capillary leak syndrome or systemic inflammatory response syndrome (e.g., tachypnea, tachycardia,
            hypotension, pulmonary edema). If either is suspected, immediately DC IV, institute supportive measures and notify physician.
         </li>
<li>Monitor I&amp;O rates and pattern and watch for S&amp;S of dehydration, including dizziness, lightheadedness, fainting spells, or
            decreased urine output. 
         </li>
<li>Withhold drug and notify physician if hypotension develops for any reason during 5-d period of drug administration.</li>
<li>Lab tests: Baseline and periodic CBC and platelet counts (more frequent with cytopenias); frequent LFTs and kidney function
            test during the 5 d of clofarabine therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any distressing adverse effect of therapy to physician.</li>
<li>Use effective measures to avoid pregnancy while taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>